Frossard Nelly, Coïc Alexandra, Saguet Thibaut, Coïc Alain, Himbert Franck, Do Quoc Tuan, Galzi Jean-Luc, Suehs Carey, Guillaumet Gerald, Bonnet Pascal, Bernard Philippe
Faculty of Pharmacy, UMR7200, LIT, CNRS-Strasbourg University, Illkirch, France.
GreenPharma SAS, Orléans, France.
Int J Cosmet Sci. 2024 Jun;46(3):468-477. doi: 10.1111/ics.12948. Epub 2024 Feb 7.
Atopic dermatitis has a marked economic impact and affects the quality of life. A cosmetic compound with an innovative strategy is proposed here as a small chemical neutraligand, GPN279 (previously identified as a theophylline derivative), that binds and potently neutralizes the TARC/CCL17 chemokine, activating the Th2 cell-expressed CCR4 receptor.
Our objective was to evaluate the safety and activity of topically applied GPN279 in mild-to-moderate atopic dermatitis patients in a randomized, double-blind, placebo-controlled, parallel group trial. Such cosmetic active ingredient targeting dry skin with an atopic tendency would open a parallel strategy to the pharmaceutical approach, in particular for mild to moderate subjects, as an alternative to reduce the evolution towards severe forms of atopy.
This 4-week trial included adults with mild-to-moderate atopic dermatitis, according to the SCORAD index. Patients were randomized into two groups treated by topical applications of either an emulsion containing 0.44% GPN279 in placebo on skin lesions or the placebo (4.56% glycerin). Clinical activity was evaluated with the SCORAD as the primary objective. As secondary objectives, POEM, erythema, skin moisturization, its barrier function (TEWL) and safety were evaluated.
Twenty-one patients in each group completed the study. SCORAD was significantly improved in the GPN279 group vs. placebo. GPN279 also significantly improved POEM, induced a rapid and significant decrease of erythema, and improved skin moisture. GPN279 and placebo were well tolerated throughout the study.
A cosmetic cream comprising the CCL17 neutraligand GPN279 improved the skin barrier and physiology criteria in patients with mild-to-moderate atopic dermatitis.
特应性皮炎具有显著的经济影响并会影响生活质量。本文提出一种采用创新策略的化妆品化合物，即一种小分子化学中性配体GPN279（先前被鉴定为茶碱衍生物），它能结合并有效中和TARC/CCL17趋化因子，激活Th2细胞表达的CCR4受体。
我们的目的是在一项随机、双盲、安慰剂对照、平行组试验中，评估局部应用GPN279对轻至中度特应性皮炎患者的安全性和活性。这种针对有特应倾向的干性皮肤的化妆品活性成分将开辟一条与药物治疗方法并行的策略，特别是对于轻至中度患者，作为减少向重度特应形式发展的一种替代方法。
这项为期4周的试验纳入了根据SCORAD指数诊断为轻至中度特应性皮炎的成年人。患者被随机分为两组，一组在皮肤损伤处局部应用含0.44%GPN279的安慰剂乳液，另一组应用安慰剂（4.56%甘油）。以SCORAD作为主要指标评估临床活性。作为次要指标，评估POEM、红斑、皮肤保湿、其屏障功能（经皮水分流失）和安全性。
每组21名患者完成了研究。与安慰剂组相比，GPN279组的SCORAD有显著改善。GPN279还显著改善了POEM，使红斑迅速且显著减少，并改善了皮肤水分。在整个研究过程中，GPN279和安慰剂的耐受性良好。
一种含有CCL17中性配体GPN279的化妆品乳膏改善了轻至中度特应性皮炎患者的皮肤屏障和生理指标。
